A Single Arm, Prospective, Open Label, Multi Center, Phase Ib Study to Evaluate the Safety, Tolerability and Initial Efficacy of a Single Intra-tumoral Injection of IntraGel's Polymer-based Cisplatin-loaded Gel (TumoCure) in Subjects With Progressive or Radio-resistant Primary Head and Neck Tumor
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Cisplatin (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors Intragel
Most Recent Events
- 07 Oct 2024 Planned End Date changed from 1 Jun 2024 to 1 Jul 2025.
- 07 Oct 2024 Planned primary completion date changed from 15 Nov 2023 to 15 May 2025.
- 06 Mar 2023 Planned End Date changed from 1 Nov 2022 to 1 Jun 2024.